<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119346">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910870</url>
  </required_header>
  <id_info>
    <org_study_id>META1 - CJP4.1</org_study_id>
    <nct_id>NCT01910870</nct_id>
  </id_info>
  <brief_title>Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate of cisplatin - metronomic cyclophosphamide treatment</measure>
    <time_frame>18 months and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free progression</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of cisplatin - metronomic cyclophosphamide association</measure>
    <time_frame>18 months and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors to response and/or resistance treatment</measure>
    <time_frame>18 months and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks</description>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronomic Cyclophosphamide</intervention_name>
    <description>150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks</description>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 ans,

          -  Performance status &lt; 2,

          -  Patient with metastatic breast cancer stade IV triple negative histologically
             confirmed

          -  Measurable or not disease but radiologically evaluable (RECIST 1.1),

          -  Negative Hormonal Receptors (Estrogens and/or Progesterone), HER-2 negative (Score 0
             or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),

          -  Patient with a progression during or after an anthracyclines and/or taxanes treatment
             receiving in neo-adjuvant or adjuvant regimen according to a resistance defined as a
             documented disease progression in the last 12 month after the last dose of taxanes or
             anthracyclines,

          -  Patient non previously treated by platinum salts,

          -  Hematological Functions: Neutrophiles ≥ 1,5.109/L, Platelets ≥ 100.109/L, Leucocytes
             &gt; 3 000/mm3, Hb &gt; 9g/dL,

          -  Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal value (UNV), ASAT ≤ 2 ,5
             time UNV, ALAT ≤ 2,5 time UNV, Alkaline Phosphatase ≤ 2,5 time UNV (&lt; 5 time UNV if
             case of hepatic metastasis),

          -  Renal Functions: Creatinine Clearance ≥ 60 mL/min,

          -  Patient signed the consent study form,

          -  Patient affiliated to a social security regimen (law of 9 August 2004).

        Exclusion Criteria:

          -  Male Patients,

          -  Unknown hormonal Receptors

          -  Positive HER-2 (Score 3 in IHC or positive FISH)

          -  Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be
             pregnant in the 6 months after the end of treatment,

          -  Patient not using contraceptive treatment during the treatment or after the 6 months
             after the end of treatment,

          -  Patient is a ward,

          -  Patient suffering from a non compatible disease with the enrollment in the study,

          -  Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically
             significant cardiovascular disease (including myocardiac infarct, unstable angina,
             symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) &lt; 1 year
             before the study enrollment or randomisation,

          -  Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2),
             meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases
             unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).

          -  Uncontrolled diabetes,

          -  Psychiatric or neurological significant abnormality,

          -  Peripheric Neuropathy &gt; grade 2,

          -  Antecedent of hypersensibility to one of study treatment or one of used excipients,

          -  Urinary tract infection or acute hemorrhagic cystitis in progress

          -  Concomitant treatment with a medicine containing phenytoin or medication received in
             the context of a trial, or participation in another therapeutic clinical trial within
             &lt;30 days prior treatment with chemotherapy.

          -  Geographically unstable patient in the next 6 months or remaining distance to the
             treatment center making it difficult to follow in the study,

          -  Known history of abuse of narcotic or other drug or alcohol

          -  History of surgery within 28 days before the start of treatment,

          -  Patient unwilling or unable to comply with the requirements of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
    <phone>+33473278482</phone>
    <email>jmnabholtz@cjp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nassera CHALABI, PhD</last_name>
    <phone>+33473278454</phone>
    <email>nassera.chalabi@cjp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hopistalier Henri Mondor</name>
      <address>
        <city>Aurillac</city>
        <zip>15000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <phone>+33473278482</phone>
      <email>jmnabholtz@cjp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nassera CHALABI, PhD</last_name>
      <phone>+33473278454</phone>
      <email>nassera.chalabi@cjp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela BURLACU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médico-Chirurgical Les Tronquières</name>
      <address>
        <city>Aurillac</city>
        <zip>15000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel KAREH, MD</last_name>
      <phone>+33471043336</phone>
      <email>drmichelkareh@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Michel KAREH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <phone>4-73-27-84-82</phone>
      <phone_ext>+33</phone_ext>
      <email>jmnabholtz@cjp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nasséra CHALABI, PhD</last_name>
      <phone>4-73-27-84-54</phone>
      <phone_ext>+33</phone_ext>
      <email>nassera.chalabi@cjp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohun R.K. BAHADOOR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CHOLLET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale DUBRAY-LONGERAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle VAN PRAAGH-DOREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela BURLACU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Emile Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <phone>+33473278482</phone>
      <email>jmnabholtz@cjp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nassera CHALABI, PhD</last_name>
      <phone>+33473278454</phone>
      <email>nassera.chalabi@cjp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte MONANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Montluçon</name>
      <address>
        <city>Montluçon</city>
        <zip>03100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <phone>+33473278482</phone>
      <email>jmnabholtz@cjp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nassera CHALABI, PhD</last_name>
      <phone>+33473278454</phone>
      <email>nassera.chalabi@cjp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Marc NABHOLTZ, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale DUBRAY-LONGERAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early-relapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
